Author | Sergio Giralt, MD


Nonmyeloablative Preparative Regimens for Allogeneic Hematopoietic Transplantation

January 01, 2003

ByRichard Champlin, MD|Issa F. Khouri, MD|Paolo Anderlini, MD|Marcos J. G. De Lima, MD|Chitra Hosing, MD|John Mcmannis, PhD|Jeffrey Molldrem, MD|Naoto Ueno, MD|Sergio Giralt, MD

High-dose myeloablative therapy with allogeneic hematopoietictransplantation is an effective treatment for hematologic malignancies,but this approach is associated with a high risk of complications.The use of relatively nontoxic, nonmyeloablative, or reduced-intensitypreparative regimens still allows engraftment and the generation ofgraft-vs-malignancy effects, is potentially curative for susceptiblemalignancies, and reduces the risk of treatment-related morbidity.Two general strategies along these lines have emerged, based on theuse of (1) immunosuppressive chemotherapeutic drugs, usually apurine analog in combination with an alkylating agent, and (2) lowdosetotal body irradiation, alone or in combination with fludarabine(Fludara).

Reinventing Bone Marrow Transplantation

May 01, 1999

ByRichard Champlin, MD|Issa F. Khouri, MD|Stephen Komblau, MD|Jeffrey Molldrem, MD|Sergio Giralt, MD

The therapeutic benefit of allogeneic hematopoietic transplantation is due largely to an immune graft-vs-malignancy effect. Most of the evidence for such an effect has come from studies of allogeneic transplantation in